MX2023007347A - Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. - Google Patents

Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.

Info

Publication number
MX2023007347A
MX2023007347A MX2023007347A MX2023007347A MX2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A
Authority
MX
Mexico
Prior art keywords
alcoholic steatohepatitis
oxygen
treatment
fatty acids
combination therapies
Prior art date
Application number
MX2023007347A
Other languages
English (en)
Spanish (es)
Inventor
David Alan Fraser
Original Assignee
Northsea Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northsea Therapeutics B V filed Critical Northsea Therapeutics B V
Publication of MX2023007347A publication Critical patent/MX2023007347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023007347A 2020-12-22 2021-12-21 Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. MX2023007347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128996P 2020-12-22 2020-12-22
PCT/IB2021/062115 WO2022137125A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2023007347A true MX2023007347A (es) 2023-08-16

Family

ID=79283090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007347A MX2023007347A (es) 2020-12-22 2021-12-21 Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.

Country Status (9)

Country Link
US (1) US20240325336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267124A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554524A (cg-RX-API-DMAC7.html)
KR (1) KR20230128307A (cg-RX-API-DMAC7.html)
CN (1) CN116829139A (cg-RX-API-DMAC7.html)
AU (1) AU2021405273A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201254A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007347A (cg-RX-API-DMAC7.html)
WO (1) WO2022137125A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
TW201138832A (en) 2010-01-20 2011-11-16 Pronova Biopharma Norge As Salicylate fatty acid derivatives
SG10201509127YA (en) * 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2014132135A2 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2016156912A1 (en) 2015-04-01 2016-10-06 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
EP3350165B1 (en) * 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
MX2019007789A (es) * 2016-12-28 2019-10-21 Modunex Bio Corp Terapia de combinacion para esteatohepatitis no alcoholica (nash) y fibrosis hepatica.
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
IL308604B2 (en) * 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20220047553A1 (en) * 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Also Published As

Publication number Publication date
US20240325336A1 (en) 2024-10-03
JP2023554524A (ja) 2023-12-27
CN116829139A (zh) 2023-09-29
CA3201254A1 (en) 2022-06-30
EP4267124A1 (en) 2023-11-01
AU2021405273A1 (en) 2023-08-10
KR20230128307A (ko) 2023-09-04
WO2022137125A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
PH12020550784A1 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
ES2242768T3 (es) Composiciones destinadas al tratamiento de la disfuncion sexual, que contienen un donante no y un antioxidante.
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
AU7890701A (en) Methods of therapy with thrombin derived peptides
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
GB0021317D0 (en) Transdermal pharmaceutical delivery composition
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
EP1677806A4 (en) METHOD FOR THE TREATMENT OF ACUTE AND HYALURONIC ACIDIFICATION CAUSED BY EXCESSIVE INJURY AND STUPIDATION
PL2014293T3 (pl) Wykorzystywanie gazowego argonu do leczenia neurointoksykacji
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
MX2022015760A (es) Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
MX2025001118A (es) Terapia de combinacion contra el cancer que incluye un inhibidor de bcl-2
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
UA97961C2 (ru) Способ лечения и/или улучшения диссеминированного внутрисосудистого свертывания крови
PE20020362A1 (es) Inhibidores de aminotransferasa que dependen del amino acido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas
IS2384B (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
MX2022013789A (es) Composición acuosa antimicrobiana útil como un material terapéutico.
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
MX2022012982A (es) Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.
RU2008124898A (ru) Фармацевтическая композиция для наружного применения
MXPA02001219A (es) Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.